Increased cyclin E expression, either by CCNE1 gene amplification, copy-number gain, or elevated protein expression, is associated with poor clinical outcomes and resistance to DNA-damaging drugs in ovarian cancer [24, 41]. This evidence concerns the gene CCNE1 and ovarian cancer.